

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

02 FEB 14 PM 3:

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>The Duberstein Group, Inc.</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>2100 Pennsylvania Ave, NW Ste 500</b> City <b>Washington</b> State/Zip (or Country) <b>DC 20037</b> <b>USA</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>John W. Angus, III</b>	Telephone <b>202-728-1100</b>	E-mail (optional)	5. Senate ID # <b>12675-253</b>
7. Client Name <input type="checkbox"/> Self <b>Pharmacia Corporation</b>			6. House ID # <b>31811024</b>

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  **OR** Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  >> Termination Date \_\_\_\_\_ 11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was: Less than \$10,000 <input checked="" type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	<b>EXPENSES</b> relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of o <input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033 the Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) the Internal Revenue Code

Signature \_\_\_\_\_ Date 2/14/2002



Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

**S.1135, Medicare Reform Act of 2001, Medicare prescription drug benefit**

**S.358, Medicare Prescription Drug and Modernization Act of 2001, Medicare prescription drug benefit**

17. House(s) of Congress and Federal agencies contacted  
**House of Representatives**

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Angus, III, John W.</b>	
<b>Berman, Michael S.</b>	
<b>Champlin, Steven M.</b>	
<b>Duberstein, Kenneth M.</b>	
<b>Gandy, Henry M.</b>	
<b>Meyer, Daniel</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_

Date 2/14/2002

Printed Name and Title

**John W. Angus, III - Senior Vice President & GC**

Filing #e5e7e6ec-a062-469d-8b6a-2b4684fc3dc4 - Page 3 of 6

Pa



Registrant Name: **The Duberstein Group, Inc.**

Client Name: **Pharmacia Corporation**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **PHA** (one per page)

16. Specific Lobbying issues

**H.R.2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2002, Reimportation of US drugs from abroad**

**H.R.946, North American Prescription Price Equity Act of 2001, Reimportation of US drugs from abroad**  
**S.1229, Personal Prescription Drug Import Fairness Act, Reimportation of US drugs from abroad**

17. House(s) of Congress and Federal agencies contacted  
**House of Representatives**

Check if None


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Angus, III, John W.</b>	
<b>Berman, Michael S.</b>	
<b>Champlin, Steven M.</b>	
<b>Duberstein, Kenneth M.</b>	
<b>Gandy, Henry M.</b>	
<b>Meyer, Daniel</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature



Date **2/14/2002**

Printed Name and Title

**John W. Angus, III - Senior Vice President & GC**

Filing #e5e7e6ec-a062-469d-8b6a-2b4684fc3dc4 - Page 5 of 6

D.

